In this study we investigated the anti-cancer properties of CK-3 (Figure 1A), a dual inhibitor of the PI3K/AKT/mTOR and MAPK/ERK pathways, on multiple HCC cell lines. Here, KRT3 is linked to hepatocellular carcinoma.